Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

While antipsychotics can be effective for some patients, they come with well-known side effects, including an increased risk ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...